CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01744912
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:40.120963+00:00
Published At: 2022-05-11T00:00:00+00:00
Record Updated At: 2022-05-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-Hodgkins Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "B-cell Lymphomas", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Waldenstrom\u0027s Macroglobulinemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-05-11"
protocolSection.identificationModule.nctId: "NCT01744912"
protocolSection.identificationModule.officialTitle: "A Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid\u00ae) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.